The initiation of a Phase 1/2 study is a significant milestone for Bolt Biotherapeutics, indicating progress in the development of BDC-3042. If the study yields positive results, it could potentially lead to regulatory approval and commercialization, which would likely have a positive impact on the company's stock. However, the outcome of the study is uncertain at this stage, hence the confidence score is not at the maximum.